// App-Quantinova.ai

4308 : A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Deborah Thomas

  • Gautam Borthakur

  • Farhad Ravandi

  • Naveen Pemmaraju

  • Naval Daver

  • Alfonso Quintas-Cardama

  • Melanie Baccus

  • Rebecca Garris

  • Elias J. Jabbour

  • Hagop M. Kantarjian

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Pancreatitis

  • Venous thrombosis

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Pegaspargase

  • PEG-asparaginase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Asparaginase

  • Vincristine

  • Fibrinogen (IV)

  • Nilotinib

  • Rituximab

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • lipase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved